Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia.

15-Lipoxygenase-2 (15-LOX-2) synthesizes 15-S-hydroxyeicosatetraenoic acid (15-S-HETE), an endogenous ligand for the nuclear receptor, peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Several studies have described an inverse relationship between 15-LOX-2 and PPAR-gamma expression in normal versus tumor samples. To systematically determine if this is a ubiquitous phenomenon, we used a variety of epithelial and nonepithelial cells and some tissues to further evaluate the extent of this inverse relationship. The levels of mRNA or protein were measured by reverse transcriptase polymerase chain reaction or Western gray level intensity, whereas distribution was determined by in situ hybridization or immunofluorescence. 15-S-HETE was measured by liquid chromatography/tandem mass spectrometry. Normal epithelial cells/samples generally expressed high levels of 15-LOX-2 along with the enzyme product 15-S-HETE, but both levels were reduced in cancer cells/samples. In contrast, most cancer cells expressed high levels of PPAR-gamma mRNA and protein, which were absent from normal epithelial cells. Overall, the inverse relationship between these two genes was primarily restricted to epithelial samples. Forced expression of PPAR-gamma reduced 15-LOX-2 protein levels in normal cells, whereas forced expression of 15-LOX-2 in tumor cells suppressed PPAR-gamma protein levels. These results suggest that feedback mechanisms may contribute to the loss of 15-LOX-2 pathway components, which coincide with an increase in PPAR-gamma in many epithelial cancers.

[1]  J. Palmblad,et al.  Effects of auranofin on leukotriene production and leukotriene stimulated neutrophil function , 1984, Agents and Actions.

[2]  A. Sabichi,et al.  Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  Toshiaki Tanaka,et al.  Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress. , 2004, Metabolism: clinical and experimental.

[4]  O. D. Golenko,et al.  Arachidonic Acid Metabolism in Growth Control of A549 Human Lung Adenocarcinoma Cells , 2002, Biochemistry (Moscow).

[5]  S. Lippman,et al.  Alleviating the Suppression of Glycogen Synthase Kinase-3β by Akt Leads to the Phosphorylation of cAMP-response Element-binding Protein and Its Transactivation in Intact Cell Nuclei* , 2003, Journal of Biological Chemistry.

[6]  R. Mansel,et al.  Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[7]  Jeffrey S. Morris,et al.  The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-δ to induce apoptosis in colorectal cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Morris,et al.  Lipids and the exocytotic machinery of eukaryotic cells. , 2003, Current opinion in cell biology.

[9]  R. Newman,et al.  Subcellular Localization and Tumor-suppressive Functions of 15-Lipoxygenase 2 (15-LOX2) and Its Splice Variants* , 2003, Journal of Biological Chemistry.

[10]  C. Glass,et al.  Differential recruitment of the coactivator proteins CREB-binding protein and steroid receptor coactivator-1 to peroxisome proliferator-activated receptor gamma/9-cis-retinoic acid receptor heterodimers by ligands present in oxidized low-density lipoprotein. , 2003, The Journal of endocrinology.

[11]  T. Saruta,et al.  Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/dbmice , 2003 .

[12]  S. Lippman,et al.  Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. , 2003, Neoplasia.

[13]  G. van Meer,et al.  Lipid microdomains, lipid translocation and the organization of intracellular membrane transport (Review) , 2003, Molecular membrane biology.

[14]  S. Shuaib Nasser,et al.  Products of 15‐lipoxygenase: are they important in asthma? , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[15]  S. Wenzel,et al.  Expression and activation of 15‐lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  Dhyan Chandra,et al.  Evidence That Arachidonate 15-Lipoxygenase 2 Is a Negative Cell Cycle Regulator in Normal Prostate Epithelial Cells* 210 , 2002, The Journal of Biological Chemistry.

[17]  R. Murphy,et al.  Leukotriene B4 production in human mononuclear phagocytes is modulated by interleukin-4-induced 15-lipoxygenase. , 2002, The Journal of pharmacology and experimental therapeutics.

[18]  Jie Zhu,et al.  Mucin-producing elements and inflammatory cells. , 2002, Novartis Foundation symposium.

[19]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[20]  P. Shankaranarayanan,et al.  Acetylation by Histone Acetyltransferase CREB-binding Protein/p300 of STAT6 Is Required for Transcriptional Activation of the 15-Lipoxygenase-1 Gene* , 2001, The Journal of Biological Chemistry.

[21]  M. Flemmer,et al.  Mechanism of action of thiazolidinediones. , 2001, Current opinion in investigational drugs.

[22]  R. Newman,et al.  Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. , 2001, Analytical biochemistry.

[23]  T. Eling,et al.  15-Lipoxygenase-1 Metabolites Down-regulate Peroxisome Proliferator-activated Receptor γ via the MAPK Signaling Pathway* , 2001, The Journal of Biological Chemistry.

[24]  B. Ljung,et al.  Pharmacological treatment of insulin resistance in obesity. , 2001, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[25]  A. Brash,et al.  15-Lipoxygenase-2 expression in benign and neoplastic sebaceous glands and other cutaneous adnexa. , 2001, The Journal of investigative dermatology.

[26]  C. Glass,et al.  Cyclopentenone prostaglandins: New insights on biological activities and cellular targets , 2001, Medicinal research reviews.

[27]  F. Marks,et al.  A gene cluster encoding human epidermis-type lipoxygenases at chromosome 17p13.1: cloning, physical mapping, and expression. , 2001, Genomics.

[28]  A. Sabichi,et al.  Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. , 2001, Cancer research.

[29]  Rajnish A. Gupta,et al.  15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. , 2001, Cancer research.

[30]  T. Watanabe,et al.  Expression of 15-lipoxygenase-1 is regulated by histone acetylation in human colorectal carcinoma. , 2001, Carcinogenesis.

[31]  C. Glass,et al.  Regulation of Macrophage Gene Expression by the Peroxisome Proliferator-Activated Receptor-γ , 2001, Hormone Research in Paediatrics.

[32]  J. Holder,et al.  PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer , 2000 .

[33]  T. Fujiwara,et al.  Troglitazone and related compounds: therapeutic potential beyond diabetes. , 2000, Life sciences.

[34]  C. Coffey,et al.  Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. , 2000, Human pathology.

[35]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[36]  C. Glass,et al.  15-Deoxy-Δ12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway , 2000 .

[37]  R. Kim,et al.  Identification of Amino Acid Determinants of the Positional Specificity of Mouse 8S-Lipoxygenase and Human 15S-Lipoxygenase-2* , 2000, The Journal of Biological Chemistry.

[38]  D. Straus.  15-deoxy Δ^ -PGJ2 inhibits multiple steps in the NF-kappaB signaling pathway , 2000 .

[39]  M. Blázquez,et al.  Basic mechanisms of secretion: sorting into the regulated secretory pathway. , 2000, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[40]  A. Brash.  Lipoxygenases: Occurrence, Functions, Catalysis, and Acquisition of Substrate* , 1999, The Journal of Biological Chemistry.

[41]  T. Willson,et al.  Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase , 1999, Nature.

[42]  A. Brash,et al.  15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. , 1999, The American journal of pathology.

[43]  H. Kamitani,et al.  Expression of 15-Lipoxygenase by Human Colorectal Carcinoma Caco-2 Cells during Apoptosis and Cell Differentiation* , 1998, The Journal of Biological Chemistry.

[44]  H P Koeffler,et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  C. Glass,et al.  Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein , 1998 .

[46]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[47]  A. Malkinson,et al.  Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. , 1998, Experimental lung research.

[48]  Robert Fletterick,et al.  The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity , 1997, Nature Structural Biology.

[49]  S. Prigge,et al.  Structure and mechanism of lipoxygenases. , 1997, Biochimie.

[50]  F. Sarkar,et al.  Production of 13-hydroxyoctadecadienoic acid (13-HODE) by prostate tumors and cell lines. , 1997, Biochemical and biophysical research communications.

[51]  J. Auwerx,et al.  The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.

[52]  A. Brash,et al.  Discovery of a second 15S-lipoxygenase in humans. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[53]  C. Glass,et al.  Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors , 1997, Molecular and cellular biology.

[54]  C. Funk,et al.  Disruption of 12/15-Lipoxygenase Expression in Peritoneal Macrophages , 1996, The Journal of Biological Chemistry.

[55]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[56]  Kai Yu,et al.  Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids (*) , 1995, The Journal of Biological Chemistry.

[57]  A. Ichikawa,et al.  Biological actions of δ12-prostaglandin J2 , 1995 .

[58]  R. Djukanović,et al.  15-Lipoxygenase Immunoreactivity in Normal and in Asthmatic Airways , 1995 .

[59]  R. Lotan,et al.  Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. , 1994, Cancer research.

[60]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[61]  H. Chan,et al.  Overexpression, purification and characterization of human recombinant 15-lipoxygenase. , 1993, Biochimica et biophysica acta.

[62]  J. Bousquet,et al.  Functional and phenotypic characteristics of bronchial epithelial cells obtained by brushing from asthmatic and normal subjects , 1993, Allergy.

[63]  Christine Dreyer,et al.  Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.

[64]  I. Issemann,et al.  The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. , 1992, The EMBO journal.

[65]  J. Laborda,et al.  36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. , 1991, Nucleic acids research.

[66]  M. Hamberg,et al.  15(S)-hydroxyeicosatetraenoic acid (15-HETE) is the major arachidonic acid metabolite in human bronchi. , 1991, Advances in prostaglandin, thromboxane, and leukotriene research.

[67]  L. Allegra,et al.  Nedocromil sodium prevents the release of 15-hydroxyeicosatetraenoic acid from human bronchial epithelial cells exposed to toluene diisocyanate in vitro. , 1990, International archives of allergy and applied immunology.

[68]  Richard G. Sleight,et al.  Differences in intracellular transport of a fluorescent phosphatidylcholine analog in established cell lines. , 1989, Journal of cell science.

[69]  R. Dixon,et al.  Cloning and expression of human arachidonate 15-lipoxygenase. , 1989, Transactions of the Association of American Physicians.

[70]  T. Eling,et al.  Metabolism of arachidonic acid by human nasal and bronchial epithelial cells. , 1988, Archives of biochemistry and biophysics.

[71]  K. Kragballe,et al.  15-Hydroxyeicosatetraenoic acid (15-HETE) specifically inhibits LTB4-induced chemotaxis of human neutrophils. , 1988, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[72]  S. Lazarus.  The role of mast cell-derived mediators in airway function. , 1987, The American review of respiratory disease.

[73]  F. Sun,et al.  15-Hydroxyeicosatetraenoic acid is a potent inflammatory mediator and agonist of canine tracheal mucus secretion. , 1985, The American review of respiratory disease.

[74]  J. Shelhamer,et al.  Human airway monohydroxyeicosatetraenoic acid generation and mucus release. , 1983, The Journal of clinical investigation.